MedTrace Logo

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

NCT05108077 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-01-14

No results posted yet for this study

Summary

Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells

Conditions

Interventions

BIOLOGICAL

cytokine-induced killer cells

Autologous cytokine-induced killer cells injected intravenously

OTHER

Standard treatment according to the Clinical protocols

Standard treatment of bladder/renal cancer according to the Clinical protocols

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou · the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

  • Alexander Prokhorov, Dr · Belarusian State Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05108077 on ClinicalTrials.gov